See more : Terminix Global Holdings, Inc. (TMX) Income Statement Analysis – Financial Results
Complete financial analysis of Prenetics Global Limited (PRENW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Prenetics Global Limited, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Bare Metal Standard, Inc. (BRMT) Income Statement Analysis – Financial Results
- Nippon Yakin Kogyo Co., Ltd. (5480.T) Income Statement Analysis – Financial Results
- Ituran Location and Control Ltd. (ITRN) Income Statement Analysis – Financial Results
- Holoco Inc. (HLCN) Income Statement Analysis – Financial Results
- Morarka Finance Limited (MORARKFI.BO) Income Statement Analysis – Financial Results
Prenetics Global Limited (PRENW)
About Prenetics Global Limited
Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 21.74M | 275.76M | 275.85M | 65.18M | 9.23M |
| Cost of Revenue | 12.91M | 144.21M | 169.72M | 38.83M | 6.52M |
| Gross Profit | 8.83M | 131.55M | 106.13M | 26.34M | 2.72M |
| Gross Profit Ratio | 40.61% | 47.71% | 38.47% | 40.42% | 29.41% |
| Research & Development | 11.66M | 15.52M | 10.56M | 2.78M | 2.99M |
| General & Administrative | 41.44M | 96.06M | 83.99M | 16.62M | 13.19M |
| Selling & Marketing | 8.24M | 13.30M | 21.93M | 6.49M | 4.77M |
| SG&A | 49.68M | 109.36M | 105.92M | 23.11M | 17.96M |
| Other Expenses | -606.84K | -149.23M | -7.93K | -513.86K | 40.15K |
| Operating Expenses | 60.74M | 124.88M | 116.48M | 25.38M | 20.94M |
| Cost & Expenses | 73.65M | 269.09M | 286.20M | 64.21M | 27.46M |
| Interest Income | 3.92M | 472.19K | 3.98K | 8.04K | 15.51K |
| Interest Expense | 119.66K | 3.99M | 228.18K | 59.57K | 69.39K |
| Depreciation & Amortization | 7.79M | 7.54M | 7.35M | 2.43M | 2.23M |
| EBITDA | -47.90M | -214.28M | -157.70M | -1.42M | -18.57M |
| EBITDA Ratio | -220.29% | 15.67% | -58.89% | -0.87% | -200.54% |
| Operating Income | -51.91M | 207.42M | -10.35M | 967.46K | -18.23M |
| Operating Income Ratio | -238.73% | 75.22% | -3.75% | 1.48% | -197.44% |
| Total Other Income/Expenses | -4.76M | -159.80M | -159.89M | -2.91M | -69.39K |
| Income Before Tax | -56.67M | -183.31M | -170.28M | -3.90M | -20.87M |
| Income Before Tax Ratio | -260.64% | -66.47% | -61.73% | -5.99% | -226.06% |
| Income Tax Expense | -269.36K | 7.15M | 3.73M | -1.94M | -677.47K |
| Net Income | -62.72M | -190.45M | -174.02M | -1.96M | -20.20M |
| Net Income Ratio | -288.48% | -69.06% | -63.08% | -3.01% | -218.73% |
| EPS | -5.58 | -37.57 | -14.77 | -0.27 | -2.73 |
| EPS Diluted | -5.58 | -37.57 | -14.77 | -0.27 | -2.73 |
| Weighted Avg Shares Out | 11.25M | 5.07M | 11.78M | 7.40M | 7.40M |
| Weighted Avg Shares Out (Dil) | 11.25M | 5.07M | 11.78M | 7.40M | 7.40M |
Source: https://incomestatements.info
Category: Stock Reports